Abstract: A method of classifying a task includes obtaining a plurality of images via an image capturing device and an audio signal via an audio sensor for a predetermined period of time. The method further includes classifying, via a first trained machine learning model, the plurality of images to generate a list of first class probabilities and a list of first class labels. The method further includes classifying, via a second trained machine learning model, the audio signal to generate a list of second class probabilities and a list of second class labels. The method further includes determining, via a merging algorithm, a list of third class probabilities and a list of third class labels based on the lists of first and second class probabilities. The method further includes determining the task corresponding to the predetermined period of time based on the list of third class probabilities.

Abstract: A system includes at least one article of personal protective equipment, one or more industrial devices, an industrial controller device configured to output industrial controller data indicative of one or more attributes of the one or more industrial devices, and a computing device. The computing devices is configured to determine a set of one or more safety rules corresponding to a work environment at the first time and determine a change in an attribute of the one or more attributes of the one or more industrial devices. The computing device is further configured to identify an updated set of one or more worker safety rules corresponding to the work environment at the second time and determine whether the status of at least one article of personal protective equipment satisfies the updated set of one or more worker safety rules.

Abstract: The present system is directed in one embodiment to a vehicle with a cargo tank or reservoir and a pumping system, comprising a centralized controlled area network (CAN) in operative communication with a programmed computing device, e.g., a programmed logic controller (PLC) that may automate the pumping process output to automatically adjust based on demand and may further enable a pump flow rate that is infinitely adjustable to match output requirements. In other embodiments, the pump speed is no longer dependent upon engine speed or RPM. In other embodiments, the CAN may monitor for vapor at the pump inlet and automatically slow the pump speed until the vapor problem is resolved. Other embodiments may comprise the CAN integrating various vehicle and pumping systems to maximize safety and safety issue annunciations.

Abstract: The present system is directed in one embodiment to a vehicle with a cargo tank or reservoir and a pumping system, comprising a centralized controlled area network (CAN) in operative communication with a programmed computing device, e.g., a programmed logic controller (PLC) that may automate the pumping process output to automatically adjust based on demand and may further enable a pump flow rate that is infinitely adjustable to match output requirements. In other embodiments, the pump speed is no longer dependent upon engine speed or RPM. In other embodiments, the CAN may monitor for vapor at the pump inlet and automatically slow the pump speed until the vapor problem is resolved. Other embodiments may comprise the CAN integrating various vehicle and pumping systems to maximize safety and safety issue annunciations.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

Abstract: The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

Abstract: The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.

Abstract: The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.

Abstract: The invention provides methods for modulating an immune response comprising contacting an immune cell with an agent that modulates BTF4 or B7-L1 mediated signaling. BTF4 or B7-L1 mediated signaling may either be increased, to thereby downregulate the immune response, or alternatively may be decreased, to upregulate the immune response. Modulation may be either activation or inhibition, and contacting may occur in vivo or in vitro. Performance of this method in vivo is also potentially therapeutic for an individual who may benefit from the upregulation or downregulation of an immune response. Such modulation to downregulate the immune response serves as a therapeutic e.g., for an individual who has received an organ transplant, or has a condition such as an allergy, or an autoimmune disorder. Alternatively, modulation to upregulate the immune response serves as a therapeutic for an individual, e.g., who has a condition such as an immunosuppressive disorder or a tumor.